CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

doi:10.1182/bloodadvances.2025019378

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Blood advances - 28 Apr 2026

Shimony Shai, Murdock H Moses, Keating Julia, Tsai Harrison K, Sasi Archana, Gibson Christopher J, Faderl Stefan, Wagner Anthony, Dronamraju Nalina, Lin Tara L, Prebet Thomas, Cortes Jorge E, Uy Geoffrey L, Lancet Jeffrey E, Reilly Christopher R, Neuberg Donna, Stone Richard M, Lindsley R Coleman

Abstract excerpt

ABSTRACT: CPX-351 was approved for the treatment of acute myeloid leukemia (AML) using now-outdated definitions of AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML. We evaluated whether the overall survival (OS) benefit of CPX-351 over standard cytarabine plus anthracycline (7+3) therapy is confined to molecularly defined AML subgroups by performing DNA sequencing in 184 patients enrolled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Daunorubicin

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 41628350
DOI: 10.1182/bloodadvances.2025019378
PMCID: PMC13133533

Genes

TP53
DDX41

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.PMID 41628350Read ↗

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.Semantic proximity Read ↗

Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.Semantic proximity Read ↗

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.Semantic proximity Read ↗

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsSemantic proximity Read ↗

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia.Semantic proximity Read ↗

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.Semantic proximity Read ↗

Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.